Inflammatory bowel disease

Cure8 found this source from wjgnet.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Imaging. Open the original article for the full details.

Researchers and clinicians are watching new oral therapies for patients whose disease has failed biologic treatments. If supported by full data, a safe, oral drug that helps refractory Crohn’s disease and ulcerative...

This hire signals Coultreon is prioritizing commercial and development work on its SIK3 inhibitor COL-5671, which the company highlights as a potential oral treatment relevant to ulcerative colitis and Crohn’s disease.

Shows molecular correlates (reduced IL‑17 signaling and IL‑1β) linked with mucosal healing after exclusive enteral nutrition in children with Crohn's disease, which may help researchers develop biomarkers or understand...

People with UC on tofacitinib may experience asymptomatic reactivation of HSV or VZV detectable by PCR, which could be relevant for infection monitoring and vaccination discussions. The study did not find clear links to...

Pediatric-onset IBD can behave differently than adult-onset disease. Comparing conventional versus biologic approaches in children may help clarify relative effectiveness, safety, and impacts on growth and steroid...

Fatigue is a common, disabling symptom in people with quiescent IBD and currently lacks approved pharmacological treatments. This trial tests whether modafinil can safely reduce fatigue and improve daily functioning for...

Psychological distress and gut–brain interactions can worsen quality of life and IBD outcomes. A culturally tailored, scalable digital mind–body program could improve access to psychosocial care for Black and Hispanic...

Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Microbiome. The original article is from Materials today. Bio.

Endoscopic scores guide detection and treatment of postoperative Crohn's recurrence; better scoring could change who gets earlier therapy and potentially prevent clinical or surgical relapse.

Pathology reports often list microscopic findings that reflect disease activity. Knowing which histologic features are frequently seen in relapsing ulcerative colitis helps patients and clinicians interpret biopsy...

PUC often behaves differently and more aggressively than adult-onset UC; understanding pediatric‑specific causes and treatments could lead to better, more effective therapies for children.

A pooled analysis of cardiovascular risk tied to advanced IBD therapies could affect treatment decisions and monitoring plans because some immune-targeted drugs have been linked to cardiovascular safety concerns in other...

Accurate methods and dataset labels matter for researchers reproducing transcriptomic analyses and for clinicians interpreting translational implications. The corrigendum clarifies which datasets and experimental models...

Persistent or worsening colonic dilatation in ulcerative colitis can reflect severe, possibly irreversible bowel‑wall damage even when classic signs of toxic megacolon are absent. Recognizing this may prompt timely...

The paper identifies macrophage SELENOP as a regulator of oxidative stress and neutrophil behavior in Crohn’s disease samples and mouse models, pointing to a new mechanism that could become a target for future treatments...

Defining whether IBD therapies prevent long-term damage matters to patients and clinicians because it affects treatment goals and long-term care planning.

Better biomarkers could help predict relapse and guide treatment changes, reducing reliance on invasive endoscopy and improving disease control for people with IBD.

Better imaging of intestinal cells could help researchers find previously unseen changes in the gut barrier that contribute to IBD, which might eventually guide more targeted therapies or diagnostics.

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease and Diet and lifestyle. The original article is from Nutrients.

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease, Guselkumab, and IL-23 inhibitor. The original article is from Journal of clinical...

The work explores fundamental mechanisms by which inflammation may impair colonic epithelial identity and barrier integrity in ulcerative colitis — knowledge that could lead to new targets to improve mucosal healing.

This funded project aims to map how specific gut microbes shape metabolic outputs (like bile acids and hydrogen consumption) that may contribute to IBS symptoms and IBD-related metabolic lesions.

This project investigates how estrogen receptor signaling in intestinal epithelial cells drives sex-specific responses to injury and inflammation that may influence ulcerative colitis risk and progression.

Patients and clinicians struggle to predict relapse in ulcerative colitis because current endoscopic, histologic, and noninvasive biomarkers are imperfect. A tissue-based imaging and spatial-omics approach could identify...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease and Research and clinical trials. The original article is from Journal of clinical...

Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Microbiome. The original article is from Foods (Basel, Switzerland).

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Tests and monitoring. The original article is from Journal of clinical medicine.

The study links a common dietary compound (oxalate) to worsened intestinal inflammation in IBD and identifies reduced gut oxalate-transport gene activity and microbiome differences as possible mechanisms—findings that...

Better detection of enteric infections during suspected IBD flares could help avoid unnecessary escalation of immunosuppressive therapy and guide appropriate antibiotic use. This review suggests MPCR finds more pathogens...

If true, using infliximab drug-level modeling plus routine blood tests could help predict who has mucosal healing without immediate endoscopy, potentially reducing invasive procedures and improving monitoring for people...

The study shows that fecal (luminal) and mucosal microbiome and metabolite profiles capture different aspects of pediatric IBD—activity versus phenotype—so combined sampling may give a fuller picture for research and...

Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Diet and lifestyle. The original article is from Cureus.

People with IBD and their clinicians need to know whether common IBD treatments change COVID-19 risk or should be stopped. This review provides practical recommendations (continue most maintenance drugs; avoid systemic...

A blood biomarker that reliably indicates mucosal healing could reduce reliance on colonoscopy, help monitor disease activity more frequently, and better guide treatment decisions in UC.

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Gastro hep...

This review collects evidence about treatments specifically studied in monogenic forms of IBD, which can point toward precision, gene- or pathway-targeted therapies for people whose disease is caused by a single genetic...

The work identifies factors that predict loss of response to infliximab and suggests maintenance drug levels are the strongest predictor, which could influence monitoring strategies for people with Crohn's disease on...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from Digestive and liver...

The study reveals a new mechano-chemical mechanism regulating gut-homing integrin α4β7, which may help explain how lymphocytes home to inflamed intestines in IBD and points to a possible target for anti-adhesion...

Targeting IL‑1 is a promising route to reduce gut inflammation in IBD, but existing IL‑1 drugs face delivery and stability challenges. Nanocarriers could improve how these agents reach inflamed intestinal tissue, which...

Delivery method affects daily life and adherence. If you use or may use risankizumab, the on-body injector in this study was highly acceptable to most patients and caused mostly mild, local skin reactions, which may make...

Serum LRG1 is a candidate blood biomarker for mucosal inflammation in UC, but anti-TNF drugs may suppress its levels and cause false-negative results. This affects noninvasive monitoring and decisions based on LRG1...

Researchers identified COPZ1 as a shared ferroptosis-related hub gene in Crohn’s disease, ulcerative colitis, and periodontitis, which could point to a new molecular pathway linking gut and oral inflammation and a...

The mucus layer and goblet cells are central to colonic barrier function; understanding goblet cell diversity and plasticity could point to new ways to restore the mucus barrier in UC and improve disease control.

Surgeons and other clinicians managing IBD patients need to understand current biologic and immunomodulator options, their risks, and implications for surgical timing and perioperative care.

Cure8 found this source from Gastroenterology report, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and JAK inhibitor. Open the original article for the...

Severe UC flares can produce extreme but reversible hyperglycemia that may look like new-onset diabetes, so patients and clinicians should monitor and re-evaluate glucose over time rather than assuming a permanent...